These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1514 related items for PubMed ID: 23710603

  • 1. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E, Spagnoletti G, Salerno MP, Pedroso JA, Romagnoli J, Citterio F.
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [Abstract] [Full Text] [Related]

  • 2. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M.
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G, Citterio F, Favi E, Rossi E, Delreno F, De Santis I, Salerno MP, Gargiulo A, Castagneto M.
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y, Shaffer D, Kaplan B, Kim DY, Luan FL, Peddi VR, Shihab F, Tomlanovich S, Yilmaz S, McCague K, Patel D, Mulgaonkar S.
    Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
    [Abstract] [Full Text] [Related]

  • 5. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A, Felipe C, Cristelli M, Viana L, Basso G, Stopa S, Mansur J, Ivani M, Bessa A, Ruppel P, Aguiar W, Campos E, Gerbase-DeLima M, Proença H, Tedesco-Silva H, Medina-Pestana J.
    Am J Nephrol; 2017 May; 45(6):497-508. PubMed ID: 28511172
    [Abstract] [Full Text] [Related]

  • 6. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW.
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [Abstract] [Full Text] [Related]

  • 7. Ten-year observational follow-up of a randomized trial comparing cyclosporine and tacrolimus therapy combined with steroid withdrawal in living-donor renal transplantation.
    Kim J, Park J, Hwang S, Yoo H, Kim K, Park JB, Jang HR, Lee JE, Kim SJ, Kim YG, Kim DJ, Oh HY, Huh W.
    Clin Transplant; 2018 Sep; 32(9):e13372. PubMed ID: 30080284
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG, Winoto J, Chhabra D, Parker MA, Leventhal JR, Kaufman DB.
    Transplantation; 2007 May 27; 83(10):1324-9. PubMed ID: 17519781
    [Abstract] [Full Text] [Related]

  • 13. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J, Machida Y, Iwai T, Kuwabara N, Kabei K, Naganuma T, Kumada N, Kawashima H, Nakatani T.
    Clin Transplant; 2014 Jan 27; 28(1):80-7. PubMed ID: 24329776
    [Abstract] [Full Text] [Related]

  • 14. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
    Gonwa T, Johnson C, Ahsan N, Alfrey EJ, Halloran P, Stegall M, Hardy M, Metzger R, Shield C, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, VanVeldhuisen P, Leonhardt M, Fitzsimmons WE.
    Transplantation; 2003 Jun 27; 75(12):2048-53. PubMed ID: 12829910
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
    Ahsan N, Johnson C, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, VanVeldhuisen P, Salm K, Tolzman D, Fitzsimmons WE.
    Transplantation; 2001 Jul 27; 72(2):245-50. PubMed ID: 11477347
    [Abstract] [Full Text] [Related]

  • 17. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
    Gonwa T, Mendez R, Yang HC, Weinstein S, Jensik S, Steinberg S, Prograf Study Group.
    Transplantation; 2003 Apr 27; 75(8):1213-20. PubMed ID: 12717205
    [Abstract] [Full Text] [Related]

  • 18. Everolimus associated with low-dose calcineurin inhibitors, an option in kidney transplant recipients of very old donors.
    Furian L, Silvestre C, Vallese L, Baldan N, Donato P, Bonfante L, Cavallin F, Marchini F, Rigotti P.
    Transplant Proc; 2014 Dec 27; 46(10):3390-5. PubMed ID: 25498057
    [Abstract] [Full Text] [Related]

  • 19. Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients.
    Ferraresso M, Belingheri M, Ginevri F, Murer L, Dello Strologo L, Cardillo M, Parodi A, Ghirardo G, Guzzo I, Innocente A, Ghio L.
    Pediatr Transplant; 2014 Jun 27; 18(4):350-6. PubMed ID: 24802342
    [Abstract] [Full Text] [Related]

  • 20. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
    Bertoni E, Larti A, Rosso G, Zanazzi M, Di Maria L, Salvadori M.
    J Nephrol; 2011 Jun 27; 24(5):613-8. PubMed ID: 21240873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 76.